Shares of Zosano Pharma Corp. (NASDAQ:ZSAN) have earned a consensus broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company. Zosano Pharma Corp.’s rating score has declined by 100% in the last 90 days as a result of various analysts’ upgrades and downgrades.

Analysts have set a 12-month consensus target price of $7.00 for the company and are expecting that the company will post ($0.65) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Zosano Pharma Corp. an industry rank of 107 out of 265 based on the ratings given to its competitors.

A number of research analysts have recently issued reports on ZSAN shares. Zacks Investment Research lowered Zosano Pharma Corp. from a “hold” rating to a “sell” rating in a research report on Wednesday, August 31st. Ladenburg Thalmann lowered Zosano Pharma Corp. from a “buy” rating to a “neutral” rating in a research report on Thursday, August 11th.

Shares of Zosano Pharma Corp. (NASDAQ:ZSAN) opened at 0.75 on Wednesday. The stock’s market capitalization is $9.01 million. Zosano Pharma Corp. has a 52 week low of $0.66 and a 52 week high of $3.59. The stock’s 50 day moving average is $0.85 and its 200-day moving average is $1.52.

Zosano Pharma Corp. (NASDAQ:ZSAN) last announced its earnings results on Wednesday, August 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by $0.04. On average, analysts anticipate that Zosano Pharma Corp. will post ($2.39) earnings per share for the current fiscal year.

In other news, CEO Konstantinos Alataris acquired 127,389 shares of the firm’s stock in a transaction on Friday, August 19th. The shares were bought at an average price of $1.32 per share, for a total transaction of $168,153.48. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Enterprise Associates 12 New sold 23,681 shares of the firm’s stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $1.27, for a total value of $30,074.87. The disclosure for this sale can be found here. 9.68% of the stock is owned by company insiders.

A hedge fund recently bought a new stake in Zosano Pharma Corp. stock. Vivo Capital LLC acquired a new position in shares of Zosano Pharma Corp. (NASDAQ:ZSAN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 98,515 shares of the company’s stock, valued at approximately $227,000. Zosano Pharma Corp. makes up 0.1% of Vivo Capital LLC’s portfolio, making the stock its 22nd largest position. Vivo Capital LLC owned about 0.82% of Zosano Pharma Corp. as of its most recent SEC filing. 35.89% of the stock is currently owned by institutional investors and hedge funds.

About Zosano Pharma Corp.

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

5 Day Chart for NASDAQ:ZSAN

Get a free copy of the Zacks research report on Zosano Pharma Corp. (ZSAN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Zosano Pharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corp. and related companies with's FREE daily email newsletter.